Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function

Eur Radiol. 2017 Aug;27(8):3343-3352. doi: 10.1007/s00330-017-4744-9. Epub 2017 Jan 18.

Abstract

Objective: The aim of this study was to assess the safety and efficacy of extended liver venous deprivation (eLVD), i.e. combination of right portal vein embolisation and right (accessory right) and middle hepatic vein embolisation before major hepatectomy for future remnant liver (FRL) functional increase.

Methods: eLVD was performed in non-cirrhotic patients referred for major hepatectomy in a context of small FRL (baseline FRL <25% of the total liver volume or FRL function <2.69%/min/m2). All patients underwent 99mTc-mebrofenin hepatobiliary scintigraphy (HBS) and computed tomographic evaluations.

Results: Ten consecutive patients underwent eLVD before surgery for liver metastases (n = 8), Klatskin tumour (n = 1) and gallbladder carcinoma (n = 1). FRL function increased by 64.3% (range = 28.1-107.5%) at day 21. In patients with serial measurements, maximum FRL function was at day 7 (+65.7 ± 16%). The FRL volume increased by +53.4% at 7 days (+25 ± 8 cc/day). Thirty-one days (range = 22-45 days) after eLVD, 9/10 patients were resected. No post-hepatectomy liver failure was reported. Two grade II and one grade III complications (Dindo-Clavien classification) occurred. No patient died with-in 90 days following surgery.

Conclusions: eLVD is safe and provides a marked and very rapid increase in liver function, unprecedented for an interventional radiology procedure.

Key points: • eLVD is safe • eLVD provides a marked and very rapid increase in liver function • After eLVD, the FRL-F increased by 64.3% (28.1-107.5%) at day 21 • After eLVD, the maximum FRL-F was obtained at day 7 (+65.7 ± 16%) • After eLVD, the FRL volume increased by +53.4% at 7 days (+25 ± 8 cc/day).

Keywords: Hepatic vein; Liver; Portal vein embolisation; Scintigraphy; Surgery.

Publication types

  • Evaluation Study

MeSH terms

  • Aged
  • Aniline Compounds
  • Bile Duct Neoplasms / surgery
  • Embolization, Therapeutic / adverse effects
  • Embolization, Therapeutic / methods*
  • Female
  • Gallbladder Neoplasms / surgery
  • Glycine
  • Hepatectomy / adverse effects
  • Hepatectomy / methods*
  • Hepatic Veins
  • Humans
  • Imino Acids
  • Klatskin Tumor / surgery
  • Liver / blood supply*
  • Liver / diagnostic imaging
  • Liver / physiopathology
  • Liver Failure / etiology
  • Liver Failure / prevention & control
  • Liver Function Tests
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Male
  • Middle Aged
  • Organotechnetium Compounds
  • Portal Vein
  • Preoperative Care / methods
  • Radiopharmaceuticals
  • Retrospective Studies
  • Single Photon Emission Computed Tomography Computed Tomography / methods
  • Tomography, X-Ray Computed

Substances

  • Aniline Compounds
  • Imino Acids
  • Organotechnetium Compounds
  • Radiopharmaceuticals
  • technetium Tc 99m mebrofenin
  • Glycine